1. Global tuberculosis report 2020. Geneva: World Health Organization. 2020.
2. Van Cutsem G, Isaakidis P, Farley J, Nardell E, Volchenkov G, Cox H. Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key. Clin Infect Dis. 2016;62 Suppl 3:S238-43.
3. Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B. Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai. Biomed Res Int. 2016;2016:2628913.
4. Nguyen VA, Nguyen HQ, Vu TT, Nguyen NA, Duong CM, Tran TH, et al. Reduced turn-around time for Mycobacterium tuberculosis drug susceptibility testing with a proportional agar microplate assay. Clin Microbiol Infect. 2015;21(12):1084-92.
5. Kuaban C, R Bercion, G Jifon, P Cunin, KN BlackettBlackett. Acquired anti-tuberculosis drug resistance in Yaounde, Cameroon. Int J Tuberc Lung Dis. 2000;5(4):427-32.
6. Loutet MG, Davidson JA, Brown T, Dedicoat M, Thomas HL, Lalor MK. Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015. Emerging infectious diseases. 2018;24(3):524-33.
7. Falzon D, Jaramillo E, Schünemann H. The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis. European Respiratory Journal. 2011;38(Suppl 55):393.
8. Association CM. Guidelines for primary diagnosis and treatment of tuberculosis (2018). Chinese Journal of General Practitioners. 2019;18(8):709-17.
9. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, et al. TB score: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111-20.
10. Falzon D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3).
11. Treatment of tuberculosis: guidelines – 4th ed. World Health Organization. 2010.
12. Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y, et al. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis. BMC Pulm Med. 2016;16:26.
13. Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, et al. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. J Antimicrob Chemother. 2018;73(10):2838-45.
14. Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother. 2014;69(9):2420-5.
15. Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2015;21(6):992-1001.
16. Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, et al. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades. Clinical Infectious Diseases. 2019;69(8):1394-402.
17. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. The Lancet Infectious Diseases. 2010;10(6):387-94.
18. Schechter MC, Bizune D, Kagei M, Machaidze M, Holland DP, Oladele A, et al. Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia. Clin Infect Dis. 2017;65(11):1862-71.
19. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017;17(2):223-34.